Milestone Pharmaceuticals’ (MIST) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a $25.00 target price on the stock.

Milestone Pharmaceuticals Trading Down 60.9 %

Shares of MIST stock opened at $0.88 on Friday. Milestone Pharmaceuticals has a 1-year low of $0.75 and a 1-year high of $2.75. The company has a current ratio of 15.40, a quick ratio of 15.40 and a debt-to-equity ratio of 2.18. The stock has a market cap of $46.95 million, a price-to-earnings ratio of -1.09 and a beta of 1.83. The stock has a 50-day moving average of $2.00 and a 200-day moving average of $1.84.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several large investors have recently modified their holdings of the company. Toronto Dominion Bank bought a new stake in Milestone Pharmaceuticals during the fourth quarter valued at $1,770,000. Boxer Capital Management LLC acquired a new position in shares of Milestone Pharmaceuticals in the 4th quarter valued at about $729,000. Virtu Financial LLC acquired a new stake in Milestone Pharmaceuticals during the fourth quarter worth approximately $170,000. Northern Trust Corp increased its holdings in Milestone Pharmaceuticals by 112.6% in the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company’s stock worth $137,000 after purchasing an additional 30,772 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in Milestone Pharmaceuticals in the fourth quarter valued at approximately $80,000. 86.18% of the stock is currently owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.